Other Updates
New Jersey Acquisition
Subsequent to December 31, 2021, on January 7, 2022, the New Jersey Cannabis Regulatory Commission approved iAnthus New Jersey, LLC’s acquisition of 100% of the equity interests of New Jersey license holder MPX New Jersey, LLC (“MPX NJ”). On February 1, 2022, the Company closed on its acquisition of MPX NJ.
Annual General Meeting
Further to the Company’s news release dated December 17, 2021, iAnthus filed a Notice of Appeal in the Supreme Court of British Columbia (the “Court”) appealing the BC Registrar of Companies’ (the “BC Registrar”) decision dated November 19, 2021 to decline a further extension to the Company’s annual general meeting for the year 2020 (the “2020 AGM”).
The Company and the BC Registrar filed a consent order with the Court pursuant to which the Court ordered: (i) the Company’s appeal be allowed, (ii) the BC Registrar’s decision dated November 19, 2021 be set aside and (iii) the BC Registrar extend the deadline for iAnthus to hold the 2020 AGM to June 30, 2022 or some later date as the BC Registrar may, in accordance with the BC Business Corporations Act, decide.
The BC Registrar also extended the deadline for the Company to hold its annual general meeting for the year 2021 to June 30, 2022.
Non-GAAP Financial Information
This release includes certain non-GAAP financial measures as defined by the SEC. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are included in the tables above. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with GAAP.
In evaluating our business, we consider and use EBITDA as a supplemental measure of operating performance. We define EBITDA as earnings before interest, taxes, depreciation and amortization. We present EBITDA because we believe it is frequently used by securities analysts, investors and other interested parties as a measure of financial performance. We define Adjusted EBITDA as EBITDA before stock-based compensation, accretion expense, write-downs and impairments, gains and losses from changes in fair values of financial instruments, income or losses from equity-accounted investments, changes in accounting policy, non-recurring costs related to the Company’s Recapitalization Transaction, and litigation costs related to ongoing legal proceedings.
The terms EBITDA and Adjusted EBITDA are not defined under GAAP, and are not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. EBITDA and Adjusted EBITDA have limitations as an analytical tool, and when assessing the Company’s operating performance, investors should not consider EBITDA or Adjusted EBITDA in isolation, or as a substitute for net income (loss) or other consolidated income statement data prepared in accordance with GAAP. Among other things, EBITDA and Adjusted EBITDA do not reflect the Company’s actual cash expenditures. Other companies may calculate similar measures differently than us, limiting their usefulness as comparative tools. We compensate for these limitations by relying on GAAP results and using EBITDA and Adjusted EBITDA only as supplemental.
About iAnthus
iAnthus owns and operates licensed cannabis cultivation, processing and dispensary facilities throughout the United States. For more information, visit www.iAnthus.com.